Robert T. McNally, Ph.D., president and chief executive officer, commented, "During 2010 we made solid, steady progress in developing our HIV/AIDS vaccines. For 2011, our goals include advancing our Phase 1/2 therapeutic clinical program to the point of seeing crucial data from vaccinated patients, completion of patient enrollment and vaccinations in the Phase 2a trial of our preventative vaccine, and commencement of planning for the Phase 2b trial in the preventative program. In addition we expect the HIV Vaccine Trials Network (HVTN) to initiate a Phase 1 trial for the GM-CSF adjuvanted version of our preventative vaccine in the latter part of 2011."
Dr. McNally continued, "We continue to benefit from tremendous financial, operational, and technical support provided to us by the National Institutes of Health (NIH) and by the HVTN. The HVTN, funded by the NIH, is the largest worldwide clinical trials network dedicated to development and testing of promising HIV/AIDS vaccines. While we are deeply appreciative of the governmental support we receive, it does not cover all of our activities, so fund-raising is also one of our primary goals for 2011. We began the effort during 2010 and have laid the groundwork for success in 2011 through corporate capital restructuring, establishment of investment banking relat
|SOURCE GeoVax Labs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved